Welcome in, today is Friday, August fourteenth, and we begin with Chanel, where Global Cosmetics News reports first-half growth in fragrance and beauty. Chanel's fragrance and beauty division grew through the first half of this year, according to Global Cosmetics News, which characterizes the performance as strong and ties it to continued demand across the beauty portfolio. That same account sets the result against what it calls a challenging global luxury market. The contrast is the useful part: prestige beauty is again reading as the steadier line while the wider luxury cycle cools, which shapes how much weight the category is being asked to carry inside a house's mix. One caveat on sizing it. The summary we have puts no figure and no comparison base on the growth, so the direction is what is established here, not the magnitude. Alongside the result, some industry commentary shifts the frame from sales to the digital shelf. The read there is that organic product-search share in beauty is spread across more than a thousand brands, so the leaders' unpaid discoverability, and not only retail-media spend, may be an under-watched driver of momentum. Whether Chanel's first half reflects any of that is not something the reporting addresses. Also today, an ingredient developer is going direct to consumers. WWD Beauty reports Dermata is launching a brand called Tome, built around a once-weekly spicule treatment priced at forty-five dollars and meant to accelerate skin rejuvenation. Spicules are the sponge-derived micro-needles that open temporary channels in the skin, and that price puts the product squarely in the gap between a shelf serum and a clinic appointment, which is the pricing tier most actives brands have been circling for two years. That summary is all the detail the reporting carries so far. No channel, no launch window, no wider assortment. Industry reaction leans toward reading this as a category signal rather than a single launch, with some framing spicules as graduating from niche curiosity into a mainstream at-home answer to that clinic gap. A recurring note among observers is the financial backdrop of the pivot, a development-stage position with a modest cash pile and runway measured in months, which some read as making a first commercial launch unusually load-bearing. Separately, Amorepacific has a generative AI research assistant in production. Global Cosmetics News reports the company built it with the Korean telecom KT, under the name Lemon, aimed at cutting the time spent on research and on regulatory review during product development. The reduction is described in that account as dramatic, though the time savings are company-stated and we have not seen them independently verified, so treat it as a claim rather than a benchmark. Regulatory review is where multi-market launches usually stall, so compression there would read through to launch cadence more than to formulation itself. Commentary around the deployment leans toward framing the durable asset as the data layer underneath, decades of R and D records restructured so a machine can consume them, with natural-language search positioned as only the first use case built on top. Now, a few more headlines moving the trade today. CNN takes a closer look at biotech beauty, the argument being that fermentation-derived actives deliver more consistent performance than naturals, with Korean brands as early movers. And finally, Procter and Gamble has appointed chief executive Shailesh Jejurikar chairman of the board, per Global Cosmetics News, completing the transition after Jon Moeller's retirement.